BetterInvesting™ Magazine Update on Vertex Pharmaceuticals Inc. and Martin Marietta Materials Inc.
TROY, Mich., Jan. 10, 2024 /PRNewswire/ — The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) as its “Stock to Study” and Martin Marietta Materials Inc. (NYSE: MLM) as its “Undervalued Stock” in the March 2024 issue for investors’ informational and educational use.
Related news for (VRTX)
- Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
- Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
- Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
- Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia